查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1546190

全球免疫测量市场

Radioimmunoassays
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2030年全球免疫测量市场将达5.871亿美元

全球免疫测量市场预估2023年为4.709亿美元，预估至2030年将达5.871亿美元，2023-2030年分析期间复合年增长率为3.2%。免疫测量试剂和套件是本报告分析的细分市场之一，预计复合年增长率为 3.4%，到分析期结束时将达到 4.587 亿美元。分析期间，免疫测量分析仪细分市场的复合年增长率预计为 2.6%。

美国市场预估为1.256亿美元，中国预期复合年增长率为2.7%

预计 2023 年美国免疫测量市场规模将达 1.256 亿美元。中国作为全球第二大经济体，预计2023年至2030年将维持2.7%的复合年增长率，到2030年市场规模将达到9,170万美元。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 3.1% 和 2.6%。在欧洲，德国的复合年增长率预计为 3.3%。

全球免疫测量市场 - 主要趋势与驱动因素总结

免疫测量：彻底改变诊断测试

免疫测量(RIA) 是一种灵敏的实验室技术，通常用于测量血液或尿液等样本中特定抗原或荷尔蒙的浓度。此方法使用与目标分子结合的放射性标记抗原或抗体，从而可以对分析物进行准确定量。 RIA 广泛用于临床实验室来检测和监测各种医疗状况，包括荷尔蒙失调、感染疾病和癌症。此技术具有高灵敏度和特异性，特别适用于检测低水平的激素，如胰岛素、甲状腺激素和生殖激素，以及测量肿瘤标记和其他生物标记。 RIA 透过提供对疾病诊断、治疗计划和监测至关重要的准确、可靠的结果，彻底改变了诊断测试。

技术进步如何改善免疫测量？

技术进步显着提高了免疫测量的性能、安全性和便利性，使其能够有效地用于广泛的诊断应用。放射性同位素标记的创新提高了 RIA 试剂的稳定性和灵敏度，从而获得更准确和一致的结果。自动化 RIA 系统的开发简化了测试过程，减少了测定准备和分析所需的时间和精力，同时最大限度地降低了人为错误的风险。检测小型化和微孔盘格式的使用的进步提高了 RIA 通量，能够同时分析多个样品，并提高了实验室效率。此外，RIA 与酵素免疫分析法测定 (EIA) 和化学冷光检测法等其他诊断技术的整合扩大了可检测和定量的分析物范围，提供了更全面的诊断资讯。这些技术进步正在推动先进的 RIA 系统在世界各地的临床实验室中的采用。

免疫测量在医学诊断上的主要用途和优点是什么？

免疫测量广泛用于诊断应用，具有许多优点，可提高医学检测的准确性、可靠性和效率。在内分泌学中，放射免疫分析对于测量糖尿病、甲状腺疾病、生殖障碍等患者的荷尔蒙水平至关重要，为诊断和治疗计划提供重要资讯。在肿瘤学中，放射免疫分析用于检测肿瘤标记并监测癌症治疗的有效性，从而实现早期疗育和个人化治疗方法。该技术还可用于传染病检查，检测患者样本中是否有病毒和细菌抗原，有助于感染疾病的快速诊断和管理。此外，放射免疫分析也用于药物动力学测量血液中的药物浓度，以确保剂量正确并监测治疗反应。 RIA 的主要优点包括高灵敏度、特异性以及能够检测低浓度分析物，使其成为临床诊断的重要工具。

推动免疫测量市场成长的因素有哪些？

免疫测量市场的成长受到多种因素的推动。癌症、糖尿病和荷尔蒙失调等慢性病的盛行率不断上升是一个重要的驱动因素，因为这些疾病需要精确的诊断测试才能进行有效的管理。放射性同位素标记、自动化和测定小型化的技术进步也透过提高 RIA 系统的性能和效率来推动市场成长。对个人化医疗和标靶治疗的需求不断增长，进一步推动了 RIA 的采用。因为这些技术为个人化治疗计划提供了重要资讯。此外，随着医疗保健提供者寻求更准确、更可靠的诊断工具，RIAs 在传染病检查和药物动力学等领域的广泛应用也有助于市场成长。人们对提高诊断准确性和降低医疗成本的兴趣日益浓厚，也推动了临床实验室采用先进的 RIA 系统。这些因素加上诊断技术的不断创新，正在推动免疫测量市场的持续成长。

受访企业范例（44家知名企业）

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays SA
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP14331

Global Radioimmunoassays Market to Reach US$587.1 Million by 2030

The global market for Radioimmunoassays estimated at US$470.9 Million in the year 2023, is expected to reach US$587.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Radioimmunoassay Reagents & Kits, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$458.7 Million by the end of the analysis period. Growth in the Radioimmunoassay Analyzers segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$125.6 Million While China is Forecast to Grow at 2.7% CAGR

The Radioimmunoassays market in the U.S. is estimated at US$125.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$91.7 Million by the year 2030 trailing a CAGR of 2.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Radioimmunoassays Market - Key Trends and Drivers Summarized

Radioimmunoassays: Revolutionizing Diagnostic Testing

Radioimmunoassays (RIAs) are highly sensitive laboratory techniques used to measure the concentration of specific antigens or hormones in a sample, typically blood or urine. The method involves the use of radioactively labeled antigens or antibodies that bind to the target molecule, allowing for precise quantification of the substance of interest. RIAs are widely used in clinical laboratories for the detection and monitoring of various medical conditions, including hormonal disorders, infectious diseases, and cancer. The technique's high sensitivity and specificity make it particularly valuable for detecting low levels of hormones, such as insulin, thyroid hormones, and reproductive hormones, as well as for measuring tumor markers and other biomarkers. RIAs have revolutionized diagnostic testing by providing accurate and reliable results that are critical for disease diagnosis, treatment planning, and monitoring.

How Are Technological Advancements Enhancing Radioimmunoassays?

Technological advancements have significantly improved the performance, safety, and convenience of radioimmunoassays, making them more effective for a wide range of diagnostic applications. Innovations in radioisotope labeling have enhanced the stability and sensitivity of RIA reagents, allowing for more accurate and consistent results. The development of automated RIA systems has streamlined the testing process, reducing the time and labor required for assay preparation and analysis, while also minimizing the risk of human error. Advances in assay miniaturization and the use of microplate formats have increased the throughput of RIAs, enabling the simultaneous analysis of multiple samples and improving laboratory efficiency. Additionally, the integration of RIA with other diagnostic techniques, such as enzyme immunoassays (EIAs) and chemiluminescent assays, has expanded the range of analytes that can be detected and quantified, providing more comprehensive diagnostic information. These technological improvements are driving the adoption of advanced RIA systems in clinical laboratories worldwide.

What Are the Key Applications and Benefits of Radioimmunoassays in Medical Diagnostics?

Radioimmunoassays are used in a wide range of diagnostic applications, offering numerous benefits that enhance the accuracy, reliability, and efficiency of medical testing. In endocrinology, RIAs are essential for measuring hormone levels in patients with conditions such as diabetes, thyroid disorders, and reproductive health issues, providing critical information for diagnosis and treatment planning. In oncology, RIAs are used to detect tumor markers and monitor the effectiveness of cancer therapies, allowing for early intervention and personalized treatment approaches. The technique is also valuable in infectious disease testing, where it can detect the presence of viral or bacterial antigens in patient samples, aiding in the rapid diagnosis and management of infections. Additionally, RIAs are used in pharmacokinetics to measure drug levels in the blood, ensuring appropriate dosing and monitoring therapeutic responses. The primary benefits of RIAs include their high sensitivity, specificity, and ability to detect low concentrations of analytes, making them indispensable tools in clinical diagnostics.

What Factors Are Driving the Growth in the Radioimmunoassays Market?

The growth in the Radioimmunoassays market is driven by several factors. The increasing prevalence of chronic diseases, such as cancer, diabetes, and hormonal disorders, is a significant driver, as these conditions require precise diagnostic testing for effective management. Technological advancements in radioisotope labeling, automation, and assay miniaturization are also propelling market growth by enhancing the performance and efficiency of RIA systems. The rising demand for personalized medicine and targeted therapies is further boosting the adoption of RIAs, as these techniques provide critical information for individualized treatment planning. Additionally, the expanding applications of RIAs in areas such as infectious disease testing and pharmacokinetics are contributing to market growth, as healthcare providers seek more accurate and reliable diagnostic tools. The growing focus on improving diagnostic accuracy and reducing healthcare costs is also supporting the adoption of advanced RIA systems in clinical laboratories. These factors, combined with continuous innovation in diagnostic technology, are driving the sustained growth of the Radioimmunoassays market.

Select Competitors (Total 44 Featured) -

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays S.A
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Radioimmunoassays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Sensitive and Specific Diagnostic Tests Propels Market Growth
    • Increasing Use in Clinical and Research Laboratories Expands Addressable Market Opportunity
    • Technological Advancements in Radioimmunoassay Techniques Strengthen Market Position
    • Growing Focus on Early Disease Detection and Monitoring Drives Adoption of Radioimmunoassays
    • Surge in Demand for Hormone and Tumor Marker Testing Generates New Opportunities
    • Development of Automated and High-Throughput Assay Systems Sustains Market Growth
    • Expanding Applications in Endocrinology and Oncology Throws Spotlight on Market Potential
    • Growth in Personalized Medicine and Targeted Therapies Spurs Demand for Radioimmunoassays
    • Rising Adoption of Radioimmunoassays in Academic and Research Institutions Propels Market Expansion
    • Surge in Demand for Radioimmunoassays in Infectious Disease Testing Expands Market Horizons
    • Growing Awareness of the Benefits of Radioimmunoassays in Rare Disease Diagnosis Drives Market Adoption
    • Innovations in Radioactive Labeling and Detection Technologies Generate New Market Opportunities
    • Rising Demand for Radioimmunoassays in Emerging Healthcare Markets Throws Spotlight on Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Radioimmunoassays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION